Recommended Vaccinations

 

Vaccine Trade Name Abbreviation Manufacturer Doses in Routine Series Approved Ages Comments
Adenovirus Adenovirus
Type 4 & Type 7		   Barr Labs Inc. Oral
(2 Tablets)
1		 17-50 years Live: Approved for military populations
Anthrax BioThrax® AVA Emergent BioSolutions IM
3		 18-65 years Inactivated, Adj.
Cholera Vaxchora®   PaxVax Oral (Liquid)
1		 18-64 years Live Attenuated
DTaP Daptacel® DTaP sanofi IM
5		 6 weeks-6 years Inactivated, Adj.
Infanrix® DTaP GlaxoSmithKline IM
5		 6 weeks-6 years Inactivated, Adj.
DT Generic DT sanofi IM
5		 6 weeks-6 years Inactivated, Adj.: Use when pertussis is contraindicated
Haemophilus influenzae type b (Hib) ActHIB® Hib (PRP-T) sanofi IM
4		 2 months-5 years Inactivated, Adj.
(Tetanus toxoid conjugate)
Hiberix® Hib (PRP-T) GlaxoSmithKline IM
4		 6 weeks-4 years Inactivated, Adj.
(Tetanus toxoid conjugate)
PedvaxHIB® Hib (PRP-OMP) Merck IM
3		 2-71 months Inactivated, Adj.
(Meningococcal conjugate)
Hepatitis A Havrix® HepA GlaxoSmithKline IM
2		 Pediatric:
12 months-18 years
Adult: ≥19 years		 Inactivated, Adj.
Vaqta® HepA Merck IM
2		 Pediatric:
12 months-18 years
Adult: ≥19 years		 Inactivated, Adj.
Hepatitis B Engerix-B® HepB GlaxoSmithKline IM
3		 Pediatric:
Birth-19 years
Adult: ≥20 years		 Recombinant, Adj.
Recombivax HB® HepB Merck IM
3		 Pediatric:
Birth-19 years
Adult: ≥20 years		 Recombinant, Adj.
Heplisav-B® HepB Dynavax Technologies IM
2		 ≥18 years Recombinant, Adj.
Herpes Zoster (Shingles) Shingrix® RZV GlaxoSmithKline IM
2		 ≥50 years Recombinant, Adj.
Human Papillomavirus
(HPV)		 Gardasil® 9 9vHPV Merck IM
2 or 3		 9-45 years Recombinant, Adj.
ACIP recommends 9-26 years
Influenza Afluria® IIV3
IIV4		 Seqirus IM
1 or 2		 ≥5 years Inactivated
Fluad® IIV3 Seqirus IM 1 ≥65 years Inactivated, Adj.
Fluarix® IIV4 GlaxoSmithKline IM 1 or 2 ≥6 months Inactivated
Flublok® RIV4 sanofi IM 1 ≥18 years Recombinant, Egg-Free
Flucelvax® ccIIV4 Seqirus IM 1 or 2 ≥4 years Cell-Culture
FluLaval® IIV4 GlaxoSmithKline IM 1 or 2 ≥6 months Inactivated
FluMist® LAIV4 Medimmune Intranasal 1 or 2 2-49 years Live Attenuated
Fluzone® IIV3
IIV4		 sanofi IM 1 or 2 ≥6 months Inactivated
Fluzone®
High-Dose		 IIV3 sanofi IM 1 ≥65 years Inactivated
Japanese encephalitis Ixiaro® JE Valneva IM 2 ≥2 months Inactivated, Adj.
Measles, Mumps, Rubella M-M-R® II MMR Merck SC 2 ≥12 months Live Attenuated
Meningococcal Menactra® MCV4
MenACWY-D		 sanofi IM 2 9 months-55 years Inactivated (Diphtheria toxoid conjugate)
Menveo® MCV4
MenACWY-CRM		 GlaxoSmithKline IM
2		 2 months-55 years Inactivated
(CRM197 conjugate)
Trumenba® MenB-FHbp Pfizer IM
2 or 3		 10-25 years Recombinant, Adj.
Bexsero® MenB-4C GlaxoSmithKline IM
2		 10-25 years Recombinant, Adj.
Pneumococcal Pneumovax® 23 PPSV23 Merck IM or SC
1		 ≥2 years Inactivated Polysaccharide
Prevnar 13® PCV13 Pfizer IM
4		 ≥6 weeks Inactivated, Adj.
(CRM197 conjugate)
Polio Ipol® IPV sanofi IM or SC
4		 ≥6 weeks Inactivated
Rabies Imovax® Rabies   sanofi IM
3 (pre-exposure)
5 (post-exposure)		 All ages Inactivated
RabAvert®   GlaxoSmithKline IM
3 (pre-exposure)
5 (post-exposure)		 All ages Inactivated
Rotavirus RotaTeq® RV5 Merck Oral (Liquid)
3		 6-32 weeks Live, Pentavalent
Rotarix® RV1 GlaxoSmithKline Oral (Liquid)
2		 6-24 weeks Live, Monovalent
Tetanus,
(reduced) Diphtheria		 Tenivac® Td sanofi IM
1 (Every 10 years)		 ≥7 years Inactivated, Adj.
(Generic) Td Massachusetts Biological Labs IM
1 (Every 10 years)		 ≥7 years Inactivated, Adj.
Tetanus, (reduced) Diphtheria,
(reduced) Pertussis		 Boostrix® Tdap GlaxoSmithKline IM
1		 ≥10 years Inactivated, Adj.
Adacel® Tdap sanofi IM
1		 10-64 years Inactivated, Adj.
Typhoid Typhim Vi®   sanofi IM
1		 ≥2 years Inactivated, Polysaccharide
Vivotif®   PaxVax Oral (Capsules)
4		 ≥6 years Live Attenuated
Varicella Varivax® VAR Merck SC
2		 ≥12 months Live Attenuated
Vaccinia (Smallpox) ACAM2000®   sanofi Percutaneous
1		 All ages Live Attenuated
Yellow Fever YF-Vax® YF sanofi SC
1		 ≥9 months Live Attenuated

1. Tdap
• Preteens between 11-12 years of age should receive 1 dose of Tdap to help boost their immunity after receiving DTaP during their childhood. If you or someone you know has not received a Tdap vaccine by 11-12 years of age, it is recommended to get one dose at their next visit to the doctor’s office or a pharmacy.
• Tdap is also recommending for woman during every pregnancy, see more information on this below.
• Do NOT get Tdap if you are younger than 7 years of age

2. Td
• 10 years after receiving Tdap, every adult should receive a Td vaccine to keep their immunity strong! In case an adult has not received the Tdap vaccine before, they should get the
• Do NOT get Td if you are younger than 7 years of age.

3. DTaP
• Given 5 times throughout a child’s initial years at 2 months, 4 months, 6 months, 15-18 months, and 4-6 years of age.
• Do NOT get DTaP if you are 7 years of age or older.

4. DT
• Given to children who SHOULD NOT receive the whooping cough (pertussis) part of the vaccine such as an allergic reaction to DTaP.
• Do NOT get DT if you are 7 years of age or older.